文献速递消化系统肿瘤

HER2阳性晚期胃或胃食管腺癌患者曲妥珠单抗长期应答的综合生物标志物分析

Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
PubMed 文献 · Eur J Cancer · 2023-02-03

该回顾性多中心研究纳入19例接受曲妥珠单抗治疗的HER2阳性转移性胃或胃食管交界癌患者,按无进展生存期(PFS≥12个月 vs PFS<12个月)分为长期应答组(n=7)和短期应答组(n=12),进行二代测序、基因表达微阵列及HER2和PD-L1免疫组化分析。结果显示长期应答组PD-L1联合阳性评分(CPS)显著更高,CPS与更长PFS相关,PD-L1阳性(CPS≥1)与CD4+记忆T细胞评分升高相关;ERBB2拷贝数及肿瘤突变负荷无法区分两组,HER2通路相关基因(如EGFR)的遗传改变和共扩增在10%患者中存在且两组分布均等。

要点

  • 长期应答组PD-L1 CPS显著高于短期应答组,且CPS与更长PFS相关。
  • PD-L1阳性(CPS≥1)与CD4+记忆T细胞评分升高相关。
  • ERBB2拷贝数和肿瘤突变负荷无法区分长期与短期应答患者。

核心结论

  • 本研究凸显了PD-L1检测在曲妥珠单抗治疗背景下的临床相关性,并通过展示PD-L1阳性组CD4+记忆T细胞评分升高提供了生物学依据。

研究设计与样本

  • 回顾性多中心研究,收集19例接受曲妥珠单抗治疗的HER2阳性转移性胃和胃食管交界癌患者的肿瘤样本。
  • 按无进展生存期(PFS≥12个月 vs PFS<12个月)将患者分为长期应答组(n=7)和短期应答组(n=12)。
  • 进行二代测序和基于微阵列的基因表达分析,以及HER2和PD-L1免疫组化检测。

主要发现

  • 长期应答组患者的PD-L1联合阳性评分(CPS)显著更高,且CPS与更长无进展生存期相关。
  • PD-L1阳性(CPS≥1)进一步与CD4+记忆T细胞评分升高相关。
  • ERBB2拷贝数以及肿瘤突变负荷无法区分短期与长期应答患者。
  • HER2通路相关基因(如EGFR)的遗传改变和共扩增与曲妥珠单抗耐药相关,存在于10%的患者中,且在两组间分布均等。

关键数值与推荐

  • 长期应答定义为PFS≥12个月,短期应答定义为PFS<12个月。
  • PD-L1阳性定义为CPS≥1。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A subgroup of patients with HER2-positive metastatic gastric and gastroesophageal junction cancers shows long-term response under trastuzumab maintenance monotherapy. Obviously, HER2 status alone is not able to identify these patients. We performed this study to identify potential new prognostic biomarkers for this long-term responding patient group. PATIENTS AND METHODS: Tumour samples of 19 patients with HER2-positive metastatic gastric and gastroesophageal junction cancer who underwent trastuzumab treatment were retrospectively collected from multiple centres. Patients were divided into long-term responding (n = 7) or short-term responding group (n = 12) according to progression-free survival (PFS≥12 months vs. PFS < 12 months). Next-generation sequencing and microarray-based gene expression analysis were performed along with HER2 and PD-L1 immunohistochemistry. RESULTS: Long-term responding patients had significantly higher PD-L1 combined positive scores (CPS) and CPS correlated with longer progression-free survival. PD-L1 positivity (CPS ≥ 1) was further associated with an increased CD4+ memory T-cell score. The ERBB2 copy number as well as the tumour mutational burden could not discriminate between short-term and long-term responding patients. Genetic alterations and coamplifications in HER2 pathway associated genes such as EGFR, which were connected to trastuzumab resistance, were present in 10% of the patients and equally distributed between the groups. CONCLUSION: The study highlights the clinical relevance of PD-L1 testing also in the context of trastuzumab treatment and offers a biological rational by demonstrating elevated CD4+ memory T-cells scores in the PD-L1-positive group.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Porth I, Hirsch D, Ceribas Y, et al. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma. Eur J Cancer. 2023. PMID: 36848831. doi:10.1016/j.ejca.2023.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。